Essential Factors To Consider When Outsourcing Clinical Development
Smaller biotech companies know that the journey from molecular discovery to late preclinical development requires years of meticulous work, primarily carried out by their own teams.
Clinical development then marks a turning point as it almost certainly requires biotech contract research: the decision about which services to outsource and to whom determines whether your clinical program proceeds on schedule or stalls in the middle of a trial.
Navigating the Biotech Lifecycle
Drug candidates embark on complex journeys from laboratory bench to patient bedside. Each development phase demands precision, expertise, and flawless execution. With clinical studies, promising compounds become very valuable assets. Your drug candidate worth $60 million during preclinical stages might reach $300 million after Phase I completion. Marketing authorization application (MAA) submission could drive that value to $1,5 billion or even much more.
These numbers reveal why clinical trial execution excellence determines your product’s commercial future.
Smart biotech companies evaluate their internal capabilities honestly before entering clinical phases as the transition from laboratory to clinical testing requires a different type of expertise: As an innovative biotech company, you might have brilliant scientists but lack the operational muscle that a CRO has for trial execution.
Scope of Biotech Contract Research
Clinical trials bring together multiple stakeholders in carefully orchestrated collaboration. Sponsor companies, contract research organizations (CROs), regulatory authorities, ethics committees, study sites, manufacturers, participants, and analytical laboratories all play specific roles. Success depends on seamless coordination between these moving parts.
CROs provide biotech contract research by study experts and thus, the operational backbone that keeps your program moving forward, as these activities require specialized expertise and established systems: Site feasibility, regulatory submissions, project management and monitoring activities, data collection and validation, statistical analysis, safety reporting and final documentation.
Key Services across Clinical Development
Some biotech companies need complete program management. Others require targeted support for specific functions where internal resources fall short. All have in common: Securing clinical development milestones requires expertise in trial conduct.
How can FGK's Biotech CRO services secure your milestones?
Clinical development success demands proven expertise that goes beyond standard execution. FGK brings 24 years of experience in biotech contract research with hundreds of trials, many of them in difficult or rare indications, including challenging patient populations where recruitment typically can fall below expectations if not handled correctly. These difficult studies require specialized approaches and sustained site engagement.
Senior management stays personally involved in project oversight, while your dedicated Project Manager maintains complete perspective across all study processes:
Regulatory Excellence Meets Data Precision
Regulatory submissions require both precision and agility. FGK CRO handles authority and ethics committee communications across multiple jurisdictions, with our Medical Writers creating your study documents and our Regulatory Experts preparing submission packages that adapt to ever evolving requirements. Our regulatory expertise spans all important inner medicine indications including pediatric trials, orphan drugs and advanced therapies.
FGK’s site monitors/CRAs maintain continuous contact with investigators and site staff throughout study conduct. Strong administrative support and proactive guidance establish the team spirit that carries sites through demanding protocols. Quick response times and dedicated support help sites maintain the conviction and resources needed for successful patient recruitment.
Data integrity builds on solid infrastructure from day one. FGK CRO’s eSolutions staff programme the software internally, giving us flexibility that external vendors cannot match.
Our data management connects monitoring activities directly to statistical analysis through systematic data cleaning, query generation and resolution, plus SAE reconciliation. CDISC SDTM and ADaM formats are provided when regulatory submissions require them.
Safety management follows clearly defined procedures with specific timelines. FGK establishes comprehensive procedures for adverse event receipt, processing, assessment, and follow-up, manages both regular Development Safety Update Reports and expedited SUSAR submissions.
FGK Clinical Research Services: Your Partner for Biotech Success
Client relationships tell the real story. Our first customer came to FGK in 2002. We have conducted more than 40 full-service clinical research projects for them since then, across multiple clinical phases. That kind of partnership doesn’t happen by accident. This longevity reflects our operational approach and commitment to client success in biotech contract research.
Martin Krauss, M.Sc.
Founder / Managing Director / Majority Shareholder
Partnership stability determines whether your clinical program reaches its destination or encounters roadblocks along the way. Clinical development journeys demand reliable guides who understand both the terrain and the destination. Our ownership structure reinforces this stability.
24 years of consistent leadership under Managing Director Martin Krauss created the foundation that sponsors depend on.
Three long-standing Senior Directors became additional shareholders in 2018, aligning their interests directly with client success. No external investors demand short-term returns that compromise your project quality.
Building Long-Term Success Through Consistency
Our colleagues stay with us for years, not months. Employee turnover below 3% means your project team knows your study inside and out. When the same team member who designed your Phase IIa protocol also manages your Phase III program, you avoid the knowledge gaps that derail timelines.
Financial health matters when selecting a biotech contract research partner. We’ve grown revenues while maintaining profitability throughout. Companies facing financial pressure cut corners on quality systems or lose key personnel mid-study. We’ve never faced that pressure because we’ve built our business on solid ground.
Recent expansion into the UK through Clinicology acquisition and establishing US presence builds on our European foundation. We handle FDA, MHRA, and EMA requirements seamlessly.
Tailored solutions for Clinical-Stage Start-up Solutions
Start-up biotech companies face resource challenges that established pharma sponsors never encounter. Budget constraints, limited personnel, and timeline pressures create unique operational demands. We understand these realities and structure our partnership approach to match your specific needs.
Your project receives dedicated attention regardless of budget size and amount of contracted services. A 6-site Phase IIa trial gets the same commitment as a 74-site Phase III program. This balanced client portfolio protects your project from resource competition or sudden priority shifts.
Study complexity determines service selection. You get transparent breakdowns showing preparation work, study conduct, data management, statistical analysis, safety oversight, and overhead charges separately.
Our pricing reflects actual project requirements rather than inflated overhead structures. You see exactly where your investment goes and can adjust the services’ scope accordingly.
Country selection flexibility maximizes your trial’s success potential. Our subsidiaries in Europe as well as the US allow optimal location recommendations based on patient prevalence, competing trials, and site expertise. When studies extend to countries without permanent FGK staff, we engage thoroughly qualified partner CROs while maintaining full subcontractor responsibility.
FAQs:
Q1. What are typical biotech contract research services by a CROs?
Contract research organizations provide services across the clinical development process, including regulatory affairs (document preparation and submissions to authorities), project management and monitoring (site selection, feasibility assessments, and source data verification), data management and biostatistics (database design, validation, and statistical analysis), medical writing (protocols, study reports, and consent forms), and medical safety (adverse event management and safety reporting).
Q2. How much does a drug candidate's value increase during clinical development?
A drug candidate’s value increases dramatically as it progresses through clinical phases. During preclinical stages, a candidate can br valued at approximately $62 million, e.g.. After completing Phase I trials, this value can rise to $237 million. By the time a marketing authorization application is submitted, the value can reach $1,509 million.
Q3. What factors should be considered when selecting a CRO partner?
Key factors include the CRO’s stability and track record, employee retention rates, financial health, regulatory expertise across multiple jurisdictions, data management capabilities, transparent pricing structures, and ability to provide personalized service regardless of project size. Additionally, consider their experience in your specific therapeutic area and their capacity to handle multi-country trials.
Q4. How long do I need biotech CRO services typically for my clinical trials?
CRO involvement spans the entire duration of a clinical trial, which varies by phase and complexity. For example, a Phase IIa trial with 60 patients across 6 sites may require 30 months of CRO involvement, covering everything from study preparation and regulatory submissions through monitoring, data management, statistical analysis, and final reporting.